Core Viewpoint - The company has announced adjustments to the grant prices of its restricted stock incentive plans for 2023 and 2025, reflecting changes due to upcoming dividend distributions and compliance with relevant regulations [11][29]. Group 1: Board Meeting and Resolutions - The fourth board meeting was held on September 26, 2025, with all seven directors present, confirming the legality and validity of the meeting [1][2]. - The board approved the adjustment of the grant price for the 2023 restricted stock incentive plan from 22.56 CNY/share to 22.48 CNY/share [11][27]. - The board also approved the adjustment of the grant price for the 2025 restricted stock incentive plan from 21.62 CNY/share to 21.39 CNY/share [5][28]. Group 2: Adjustment Reasons and Methods - The adjustments were made in light of the company's 2024 annual dividend distribution and the upcoming 2025 semi-annual dividend distribution [25][26]. - The adjustment method for the 2023 plan involved reducing the grant price by the amount of cash dividends distributed, resulting in a new price of 22.48 CNY/share [27]. - Similarly, the adjustment for the 2025 plan was calculated using the same method, leading to a new grant price of 21.39 CNY/share [28]. Group 3: Compliance and Legal Opinions - The adjustments have been reviewed and approved by the board's remuneration and assessment committee, ensuring compliance with relevant laws and regulations [30][31]. - Legal opinions from Shanghai Guangfa Law Firm and DeHeng Law Firm confirmed the legality and validity of the adjustments for both incentive plans [32][34].
上海皓元医药股份有限公司第四届董事会第十二次会议决议公告